KR102203094B1 - Composition for preventing and improving menstrual pain and skin troubles - Google Patents
Composition for preventing and improving menstrual pain and skin troubles Download PDFInfo
- Publication number
- KR102203094B1 KR102203094B1 KR1020200112986A KR20200112986A KR102203094B1 KR 102203094 B1 KR102203094 B1 KR 102203094B1 KR 1020200112986 A KR1020200112986 A KR 1020200112986A KR 20200112986 A KR20200112986 A KR 20200112986A KR 102203094 B1 KR102203094 B1 KR 102203094B1
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- composition
- present
- blood sugar
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000005171 Dysmenorrhea Diseases 0.000 title 1
- 239000008280 blood Substances 0.000 claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 35
- 235000000346 sugar Nutrition 0.000 claims abstract description 28
- 235000010804 Maranta arundinacea Nutrition 0.000 claims abstract description 14
- 235000012419 Thalia geniculata Nutrition 0.000 claims abstract description 14
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 10
- 241000332371 Abutilon x hybridum Species 0.000 claims abstract 4
- 244000241838 Lycium barbarum Species 0.000 claims abstract 4
- 244000151018 Maranta arundinacea Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 206010012601 diabetes mellitus Diseases 0.000 claims description 23
- 239000008213 purified water Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 17
- 235000013305 food Nutrition 0.000 claims description 17
- 244000025254 Cannabis sativa Species 0.000 claims description 16
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 16
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 16
- 235000009120 camo Nutrition 0.000 claims description 16
- 235000005607 chanvre indien Nutrition 0.000 claims description 16
- 210000004207 dermis Anatomy 0.000 claims description 16
- 239000011487 hemp Substances 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 235000015468 Lycium chinense Nutrition 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000003809 water extraction Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 36
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 7
- 102000004139 alpha-Amylases Human genes 0.000 abstract description 7
- 108090000637 alpha-Amylases Proteins 0.000 abstract description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 7
- 229940024171 alpha-amylase Drugs 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 3
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract description 2
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract description 2
- 241001532026 Liriope muscari Species 0.000 abstract description 2
- 230000000291 postprandial effect Effects 0.000 abstract description 2
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 235000015463 Lycium carolinianum Nutrition 0.000 abstract 1
- 241001633680 Polygonatum odoratum Species 0.000 abstract 1
- 235000021028 berry Nutrition 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 20
- 238000000605 extraction Methods 0.000 description 19
- 241000703121 Campanula rotundifolia Species 0.000 description 18
- 235000013361 beverage Nutrition 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 11
- 244000145580 Thalia geniculata Species 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 244000241872 Lycium chinense Species 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 5
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- -1 for example Substances 0.000 description 5
- 229940010454 licorice Drugs 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000061456 Solanum tuberosum Species 0.000 description 3
- 235000002595 Solanum tuberosum Nutrition 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000007937 eating Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229940124595 oriental medicine Drugs 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 235000015277 pork Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241001672694 Citrus reticulata Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 244000274050 Platycodon grandiflorum Species 0.000 description 2
- 244000086363 Pterocarpus indicus Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000020510 functional beverage Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000123643 Asparagaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000123667 Campanula Species 0.000 description 1
- 241000218235 Cannabaceae Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010051295 Neurological infection Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001625885 Polygonatum odoratum var. pluriflorum Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 208000027499 body ache Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000002044 hexane fraction Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 244000209700 shan ge teng Species 0.000 description 1
- 235000020807 short-term diet Nutrition 0.000 description 1
- 208000008842 sick building syndrome Diseases 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 황기, 도라지, 칡, 진피, 구기자, 둥굴레, 맥문동 및 마를 포함하는 혈당 강하용 조성물과 이를 포함하는 기능성 식품 조성물에 관한 것이다.The present invention relates to a composition for lowering blood sugar, including astragalus, bellflower, arrowroot, dermis, wolfberry, donggulle, liquorice and hemp, and a functional food composition comprising the same.
최근 식생활의 서구화와 스트레스, 운동부족 등으로 인하여 동맥경화, 고혈압 및 당뇨병 등의 만성생활습관성 성인병이 증가하고 있다. 특히 국내 당뇨병의 유병률은 1970년 인구 1% 미만이었으나 1980년대 말 약 3%, 1990년대 5~8%로 보고되고 있고, 2003년도 성균관의대 강북성심병원 종합검진센터의 수진자 59,174명을 분석한 결과 20대 4.3%, 30대 15.9%, 40대 21.7%, 50대 26.0%, 60대 28.1%, 70대 31.3%가 당뇨병 전단계 판정을 받음으로써 혈당관리가 요구되는 인구수가 급증하고 있는 추세에 있다.Recently, chronic lifestyle-related adult diseases such as arteriosclerosis, hypertension, and diabetes are increasing due to westernization of dietary life, stress, and lack of exercise. In particular, the prevalence of diabetes in Korea was less than 1% of the population in 1970, but it is reported to be about 3% in the late 1980s and 5-8% in the 1990s. As a result of an analysis of 59,174 patients at the General Examination Center of Sungkyunkwan Medical University Gangbuk Sacred Heart Hospital in 2003, 20 4.3% of the generations, 15.9% in their 30s, 21.7% in their 40s, 26.0% in their 50s, 28.1% in their 60s, and 31.3% in their 70s have been diagnosed as pre-diabetes, so the number of people requiring blood sugar management is increasing rapidly.
당뇨병은 인슐린(insulin)을 비롯한 글루카곤(glucagon), 글루코콜티코이드(glucocorticoid) 등의 호르몬 불균형으로 탄수화물을 비롯한 단백질, 지질 및 전해질 대사 등 생리적 대사 조절 기능의 이상이 발생하여 고혈당, 당뇨 등의 특징적인 증세를 나타내며 심각한 만성적 합병증을 가져오는 질환으로서 췌장의 베타세포가 선택적으로 손상 또는 파괴되어 인슐린의 양이 부족함으로써 발병하는 제1형 당뇨병과 인슐린 비의존성 제2형 당뇨병으로 구분된다. 지속적으로 고혈당이 조절되지 않고 만성화될 경우 고지혈증, 고혈압 및 동맥경화 등의 심혈관성 장애를 비롯하여 망막증, 신증, 신경장애, 감염증, 골감소증 등의 합병증이 초래된다. 현재까지 많은 종류의 당뇨병 치료제가 개발되어 있고 개발이 진행 중이나 만족할 만한 치료방법이나 약물은 개발되지 못하였다. 종래의 치료방법으로 인슐린 의존성 환자에게 인슐린을 직접 투여하거나 인슐린 비의존성 환자에게는 설포닐 우레아계 유도체를 투여하여 혈액내 포도당의 농도를 조절하는 방법이 있다. Diabetes is an imbalance of hormones such as insulin, glucagon, and glucocorticoid, resulting in abnormalities in physiological metabolic control functions such as protein, lipid and electrolyte metabolism, including carbohydrates, and features such as high blood sugar and diabetes. As a disease that causes serious chronic complications with symptoms, it is classified into type 1 diabetes and insulin-independent type 2 diabetes caused by insufficient insulin due to selective damage or destruction of pancreatic beta cells. If hyperglycemia is not continuously controlled and becomes chronic, complications such as retinopathy, nephropathy, neurological disorders, infections, and osteopenia, as well as cardiovascular disorders such as hyperlipidemia, hypertension and arteriosclerosis, are caused. Until now, many types of diabetes treatments have been developed and development is underway, but satisfactory treatment methods or drugs have not been developed. Conventional treatment methods include administering insulin directly to an insulin-dependent patient or administering a sulfonyl urea derivative to an insulin-independent patient to control the concentration of glucose in the blood.
그러나, 인슐린은 알레르기 반응 등의 부작용을 일으킬 수 있으며, 혈류에 도달하기 전 소화관 내에서 파괴되어 경구로 투여할 수 없으므로 주사제로만 사용되어 장시간 동안 정기적인 주사를 필요로 하는 환자에 있어 반복되는 주사로 인한 피 부의 부종을 일으키는 문제점을 가지고 있다. 그리고 톨부타미드(tolbuatmide), 글리퀴돈(gliquidone) 등의 설포닐우레아(sulfonyl urea)계 약물은 클로람페니콜, β차단제, 설파제 등과 병용시 저혈당을 야기할 수 있으며, 메트폴민(metformin) 등의 비구아니드(biguanide)계 약물은 알콜과 병용시 젖산 과다증 등을 야기하는 문제점을 가지고 있다. However, insulin can cause side effects such as allergic reactions, and it is destroyed in the digestive tract before reaching the bloodstream and cannot be administered orally. Therefore, it is used only as an injection and is used as a repeated injection for patients who require regular injection for a long time. It has a problem that causes skin swelling. In addition, sulfonyl urea drugs such as tolbuatmide and gliquidone may cause hypoglycemia when used in combination with chloramphenicol, β-blockers, and sulfa drugs, and biguanides such as metformin. (biguanide) drugs have a problem of causing an excess of lactic acid when used in combination with alcohol.
따라서 종래의 혈액내 포도당 농도를 조절하는 방법의 문제점을 극복하고자, 최근 포도당의 혈액 내 흡수 자체를 막는 새로운 방법이 시도되고 있다. 그 일환으로, 알파-글루코시다제 억제제들을 당뇨병 치료제로서 개발하는 것이 시도되고 있다. 알파-글루코시다제 저해제는 혈액내 포도당 흡수 자체를 억제하는 것으로 당뇨병 외에 비만증 및 고지방증 등의 치료 및 예방에도 이용될 수 있다.Accordingly, in order to overcome the problem of the conventional method of controlling glucose concentration in blood, a new method of preventing the absorption of glucose into the blood itself has been recently attempted. As part of that, attempts are being made to develop alpha-glucosidase inhibitors as diabetes treatments. Alpha-glucosidase inhibitors inhibit the absorption of glucose in the blood and can be used in the treatment and prevention of obesity and hyperlipidemia in addition to diabetes.
이에 본 발명자는 오랜 임상경험을 토대로, 천연물 유래 추출물을 특정 비율로 혼합하여 제조한 조성물의 현저한 혈당강하 효과를 확인하고, 본 발명을 완성하였다.Accordingly, the present inventors confirmed the remarkable hypoglycemic effect of the composition prepared by mixing extracts derived from natural products in a specific ratio based on long clinical experience, and completed the present invention.
본 발명의 목적은 황기, 도라지, 칡, 진피, 구기자, 둥굴레, 맥문동 및 마의 추출물을 포함하는 혈당 강하용 조성물을 제공하는 것이다.It is an object of the present invention to provide a composition for lowering blood sugar comprising extracts of Astragalus, bellflower, arrowroot, dermis, goji japonica, donggulle, licorice and hemp.
본 발명의 다른 목적은 상기 조성물을 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or treating diabetes comprising the composition.
본 발명의 또 다른 목적은 상기 조성물을 포함하는 당뇨병의 예방 또는 개선용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for preventing or improving diabetes comprising the composition.
상기와 같은 목적을 달성하기 위한 본 발명의 일 측면은, 황기, 도라지, 칡, 진피, 구기자, 둥굴레, 맥문동 및 마의 추출물을 포함하는, 혈당 강하용 조성물을 제공한다. One aspect of the present invention for achieving the above object provides a composition for lowering blood sugar, including extracts of Astragalus, bellflower, arrowroot, dermis, wolfberry, donggulle, liquorice and hemp.
구체적으로, 상기 조성물은 황기 50 중량부, 도라지 50 중량부, 칡 50 중량부, 진피 50 중량부, 구기자 100 중량부, 둥굴레 50 중량부, 맥문동 50 중량부 및 마 100 중량부 각각에 대하여 동일 중량부의 정제수를 첨가하고 열수 추출하여 제조한 것을 포함하는 것일 수 있다.Specifically, the composition is the same weight for each of 50 parts by weight of Astragalus, 50 parts by weight of bellflower, 50 parts by weight of arrowroot, 50 parts by weight of dermis, 100 parts by weight of wolfberry, 50 parts by weight of Donggulle, 50 parts by weight of licorice and 100 parts by weight of hemp It may include those prepared by adding negative purified water and extracting hot water.
더욱 구체적으로, 상기 조성물은 각 재료와 동일한 중량부의 정제수를 첨가한 후 순행식 무압력 추출기를 이용하여 90 내지 100℃에서 4 내지 6시간 동안 추출한 추출물을 포함하고 있으며, 각 재료별 조건은 다음과 같다.More specifically, the composition contains an extract extracted for 4 to 6 hours at 90 to 100° C. using a forward pressureless extractor after adding purified water equal to the weight of each material, and conditions for each material are as follows: same.
황기 및 도라지는 각 50 중량부에 정제수 50 중량부씩 첨가한 후 100℃에서 6시간동안 추출하였고, 칡 및 진피는 각 50 중량부에 정제수 50 중량부를 첨가한 후 98℃에서 4시간동안 추출하였으며, 구기자 100 중량부 및 50 중량부에 같은 중량부의 정제수를 첨가한 후 95℃에서 6시간동안 추출하였고, 맥문동 50 중량부 및 마 100 중량부에 같은 중량부의 정제수를 첨가한 후 92℃에서 6시간동안 추출하여 제조하였다.Astragalus and bellflower were extracted for 6 hours at 100°C after adding 50 parts by weight of purified water to each 50 parts by weight, and arrowroot and dermis were extracted for 4 hours at 98°C after adding 50 parts by weight of purified water to each 50 parts by weight, 100 parts by weight and 50 parts by weight of gojija were added and extracted for 6 hours at 95°C, and 50 parts by weight and 100 parts by weight of hemp were added to the same parts by weight of purified water at 92°C for 6 hours. It was prepared by extraction.
상기한 추출물의 세부적인 추출 조건을 벗어나는 경우, 각각의 재료에서 목적하는 유효물질이 충분히 추출되지 않아, 후술할 효과를 보이지 못할 수 있다.When the detailed extraction conditions of the extract are out of the above, the target effective substance is not sufficiently extracted from each material, and the effect to be described later may not be exhibited.
본 발명에서 상기 “황기(Astragalus propinquus)”는 장미목 콩과의 식물로서, 사포닌을 풍부하게 함유하고 있고, 효능은 한방에서는 강장, 지한(止汗), 이뇨(利尿), 소종(消腫) 효과가 있다고 하며, 황기는 독성이 거의 없어 기운을 보하는 처방에 반드시 들어가는 약재이다.In the present invention, the " Astragalus propinquus " is a plant of the rosewood legume, and contains a rich saponin, and its efficacy is tonic in oriental medicine, antiperspirant, diuretic, diuretic, and small species effect It is said that Hwanggi has little toxicity, so it is a medicinal material that must be entered in the prescription to boost energy.
본 발명에서 상기 “도라지(Platycodon grandiflorus)”는 초롱꽃과 도라지속(Platycodon)에 속하는 여러해살이풀이다. 뿌리는 식용하고, 한방에서는 도라지를 길경이라고도 하며 신경통과 편도선염 등의 약재로 사용한다. 도라지 뿌리는 사포닌이 많이 포함되어 있어서 생약(桔梗根)으로 이용되고 있으며, 특히 항염증, 항비만, 콜레스테롤 저하 등의 효과가 있는 플라티코딘 D(platycodin D)를 풍부하게 함유하고 있다. 그 밖에도 도라지 뿌리에는 칼슘, 섬유질, 철분, 무기질, 단백질, 비타민 등이 함유되어 있다. 생약은 뿌리가 굵고 내부가 충실하고, 맛이 강한 것이 우량품이다. 거담, 진해, 진통, 진정, 해열 작용이 있으며, 소염진통, 진해거담제로 사용된다. 또한 콜레스테롤을 저하시키는 효능이 있어 혈관계 질환 및 고혈압에도 효과가 있다. 도라지는 호흡기 질환이라 할 수 있는 감기는 물론 천식에도 탁월한 효능을 보이기 때문에 호흡기 질환에 노출되기 쉬운 면역력이 약한 어린아이나 노인분들, 그리고 잦은 스트레스로 인해서 면역력이 약해진 사람에게 좋다고 알려져 있다.In the present invention, the "bellflower ( Platycodon grandiflorus )" is a perennial plant belonging to the genus Campanula and Bellflower (Platycodon). The root is edible, and bellflower is also called Gilgyeong in oriental medicine, and is used as a medicine for neuralgia and tonsillitis. Bellflower root contains a lot of saponin, so it is used as a herbal medicine, and particularly, it contains a rich amount of platicodin D, which has anti-inflammatory, anti-obesity, and cholesterol-lowering effects. In addition, bellflower roots contain calcium, fiber, iron, minerals, protein, and vitamins. The herbal medicine has a thick root, a solid inside, and a strong taste. It has an expectorant, anti-inflammatory, analgesic, sedative, and antipyretic effect, and is used as an anti-inflammatory and anti-inflammatory expectorant. In addition, since it has the effect of lowering cholesterol, it is also effective in vascular disease and high blood pressure. Bellflower is known to be good for children and elderly people with weak immunity who are susceptible to respiratory disease, as well as cold asthma, and those with weakened immunity due to frequent stress.
본 발명에서 상기 “칡(Pueraria montana)”은 쌍떡잎식물 장미목 콩과의 덩굴식물로서, 목질의 줄기는 매년 굵어져서 굵은 줄기를 이루기 때문에 나무로 분류된다. 산기슭의 양지에서 자라는데, 적당한 습기와 땅속이 깊은 곳에서 잘 자라며, 줄기의 길이는 20m이상 뻗쳐있다. 칡의 뿌리는 '갈근(葛根)' 이라고 하는데, 단맛이 있고 섬유질과 전분질이 엉킨 구조로 되어있다. 약재(藥材)로 쓰이기도 하며, 말려서 끓여 먹거나 생으로 갈아먹는다.In the present invention, the "arrowroot ( Pueraria montana )" is a vine plant of the dicotyledonous plant rosewood legume, and the woody stem is classified as a tree because it becomes thicker every year to form a thick stem. It grows in the sunny place at the foot of the mountain. It grows well in the depths of the ground with moderate humidity, and the length of the stem extends over 20m. The root of arrowroot is called'galgeun', and it has a sweet taste and has a structure in which fiber and starch are tangled. It is also used as a medicinal material, and it is dried and boiled for eating or raw.
본 발명에서 상기 “진피(陳皮)”는 운향과의 귤(Citrus unshiu Markovich) 또는 동속 근연식물의 성숙한 과피를 말한다. 이 약은 특이한 냄새가 있으며 약간 자극성이 있고 맛은 맵고 쓰며 성질은 따듯하다. 비위가 허약해 일어나는 구토, 메스꺼움, 소화불량 등에 쓰이며 기(氣)를 소통시키고 습(濕)을 말리며 담(痰)을 삭이는 효능을 가진 약재로 알려져 있다. 또한, 건위(健胃), 발한(發汗), 보비(補脾), 건폐(健肺), 고기식중독, 딸꾹질, 기침, 대장, 구토(嘔吐), 소화촉진, 강심(强心), 항궤양(抗潰瘍), 항염증(抗炎症), 거담(祛痰), 몸살, 이뇨(利尿), 역기(逆氣), 곽란(亂) 등에 사용한다. 귤껍질은 가래를 삭여주는 작용을 하므로 급성 기관지염으로 인한 기침과 많은 가래, 가슴이 답답하고 더부룩한 증상에 효능이 있다고 알려져 있다.In the present invention, the "dermis (陳皮)" refers to a mandarin (Citrus unshiu Markovich) of the Unhyang family or a mature pericarp of a plant related to the genus. This medicine has a peculiar odor, is slightly irritating, tastes spicy and bitter, and has a warm nature. It is used for vomiting, nausea, and indigestion caused by weakness in the stomach. It is known as a medicinal material that has the effect of communicating energy, drying moisture, and clearing phlegm (痰). In addition, dry stomach, sweating, bobby, dry lung, meat poisoning, hiccups, cough, large intestine, vomiting, digestion promotion, strong heart, anti-ulcer (抗潰瘍), anti-inflammatory (抗炎症), geodam (祛痰), body ache, diuretic (利尿), weight (逆氣), Gwakran (亂) is used. Tangerine peels are known to be effective against coughing and a lot of phlegm caused by acute bronchitis, and the symptoms of stuffy and bloated chest.
본 발명에서 상기 “구기자”는 구기자나무(Lycium chinense) 열매를 의미하며, 한방에서 열매를 해열제·강장제로 이용하고, 차로 달이거나, 술을 담가 먹기도 한다. 구기자의 함유성분중 베타인(betaine)은 간장에 지방질이 엉키는 것을 예방하며 지방간을 치유하는 작용이 있다. 독성물질을 배출하거나 해독에 도움이 되며 꾸준히 섭취하면 노화를 방지할 뿐만 아니라 지방대사가 원활해져 효과적인 단기간 다이어트에 도움이 된다. 또 몸을 따뜻하게 해주기 때문에 지방간 제거, 신경 쇠약, 만성 간질환, 등 다양한 효능이 있다고 알려져 있다.In the present invention, the term “gojija” refers to the fruit of Lycium chinense , and the fruit is used as an antipyretic and tonic in herbal medicine, and it is also eaten with a decoction or liquor. Among the ingredients contained in wolfberry, betaine prevents fat from getting tangled in the liver and has the effect of healing fatty liver. It helps to release or detoxify toxic substances, and if you consume it consistently, it not only prevents aging, but also improves fat metabolism, which helps in an effective short-term diet. In addition, because it warms the body, it is known to have various effects such as fatty liver removal, nervous breakdown, and chronic liver disease.
본 발명에서 상기 “둥굴레(Polygonatum odoratum var. pluriflorum)”는 아스파라거스과의 여러해살이풀로 과분꽃이라고도 하며, 뿌리와 잎은 약용하며, 전분·어린잎은 식용한다. 뿌리줄기는 식용 및 자양강장제로 사용한다. 몸 안의 진액과 양기를 길러주는 자양, 폐가 건조하지 않도록 윤활하게 해주는 윤폐, 갈증을 멈추어주는 지갈, 진액을 생성해주는 생진 등의 효능이 있다. 허약체질의 개선, 폐결핵, 마른기침, 가슴이 답답하고 갈증이 나는 번갈, 당뇨병, 심장쇄약, 협심통, 소변빈삭 등을 치유하는데 응용한다. 타박상이나 삐었을 때는 강판으로 간 것을 가제에 넓게 펴서 기름종이에 붙여 환부에 바르면 효과가 있다고 알려져 있다.In the present invention, the "Dunggulle ( Polygonatum odoratum var. pluriflorum)" is a perennial plant of the Asparagus family, and is also called a pollen flower, and the roots and leaves are medicinal, and the starch and young leaves are edible. Rootstock is used as an edible and nourishing tonic. It has benefits such as nourishment that nurtures the essence and yang in the body, lubrication that lubricates the lungs so that it does not dry out, jigal that stops thirst, and saengjin that creates essence. It is applied to improve weak constitution, pulmonary tuberculosis, dry cough, chest tight and thirst alternately, diabetes, heart breakdown, angina pain, urinary pain, etc. In the case of bruises or sprains, it is known that it is effective to spread the ground with a steel plate on a gauze and attach it to an oily paper and apply it to the affected area.
본 발명에서 상기 “맥문동(Liriope platyphylla)” 비짜루목 비짜루과의 여러해살이풀이다. 한국·타이완·일본 등에 분포하며 산지의 나무 그늘에서 자란다. 불사초라고도 한다. 맥문동의 덩이뿌리를 말리면 반투명한 담황색이 되는데, 기침과 가래를 멎게하거나 폐장의 기능을 돕고 기력을 돋우는데 뛰어난 효과가 있다고 알려져 있다. 한방에서는 이것을 강장·거담·진해·강심제 등에 사용한다. 한편, 최근 새집증후군이 자주 언급되면서 맥문동의 공기정화 능력이 알려져 관심을 모으고 있다.In the present invention, the " Liriope platyphylla " is a perennial plant of the Bizarum family Bizarru family. It is distributed in Korea, Taiwan, and Japan, and grows in the shade of trees in mountainous areas. It is also called the firewood. Drying the tuber roots of Maekmundong becomes a translucent pale yellow color, which is known to have an excellent effect in stopping coughing and phlegm, helping the lungs function, and boosting energy. In oriental medicine, it is used for tonic, geodam, jinhae, and gangsimje. Meanwhile, with the recent mention of Sick House Syndrome, Maekmun-dong's air purification ability is known and attracting attention.
본 발명에서 상기 “마(Dioscorea polystachya)는 마목 마과에 속하는 덩굴성 여러해살이풀이며 동북아시아 원산이다. 얌과 매우 가까운 식물로, 산우(山芋)·서여(薯)·산약(山藥)이라고도 한다. 마는 소화기능 개선, 당뇨 개선, 혈액순환, 변비예방, 피부건강 및 자양강장의 효과가 있는 것으로 알려져 있다. 또한, 세포의 활동을 활발하게 하여 소화기 및 궤양 치료약 등에 사용되는 알란토인(Allantoin)을 풍부하게 함유하고 있다.In the present invention, the “horse ( Dioscorea polystachya ) is a tendril perennial plant belonging to the hemp family, and is native to Northeast Asia. It is a plant very close to yam, and is also called sanwoo (山芋), seoyeo (薯), and sanyak (山藥). Ma is known to be effective in improving digestive function, improving diabetes, blood circulation, preventing constipation, skin health, and nourishment. In addition, it contains an abundance of Allantoin, which is used for digestive and ulcer treatment drugs by activating cell activity.
본 발명에 있어서, 구체적으로 상기 추출물은 물, C1 내지 C4의 저급 알코올, 또는 이들의 혼합 용매로 추출된 것일 수 있다. 더욱 구체적으로는 물 또는 30 내지 80%의 에탄올 등의 탄소수 1 내지 5의 알코올 수용액일 수 있고, 가장 구체적으로는 정제수일 수 있으나, 이에 제한되지 않는다.In the present invention, specifically, the extract may be extracted with water, a lower alcohol of C 1 to C 4 , or a mixed solvent thereof. More specifically, it may be water or an aqueous alcohol solution having 1 to 5 carbon atoms such as 30 to 80% ethanol, and most specifically, purified water, but is not limited thereto.
상기 추출 용매로 정제수를 사용하는 경우, 안정성을 높일 수 있을 뿐만 아니라, 인체에 무해하기 때문에 식품이나 의약품의 조성물로 사용하기에 우수한 적합성을 나타낼 수 있으며, 안정성 확보를 위한 엄격한 공정 관리와 같은 비용 증가가 발생하지 않으므로 경제적 효과 역시 향상될 수 있다.In the case of using purified water as the extraction solvent, it is possible to not only increase stability, but also exhibit excellent suitability for use as a composition of food or pharmaceuticals because it is harmless to the human body, and increase costs such as strict process control to ensure stability The economic effect can be improved as well as does not occur.
구체적으로, 상기 추출물의 추출공정은 냉침, 온침, 가열, 환류 및 초음파 추출로 구성된 군에서 하나 이상 선택되는 방법을 단독 또는 혼합하여 사용할 수 있으며, 이에 제한되지 않고 필요에 따라 이를 적절히 변경하여 적용할 수 있다. Specifically, in the extraction process of the extract, one or more methods selected from the group consisting of cold needle, warm needle, heating, reflux, and ultrasonic extraction may be used alone or in combination, and are not limited thereto, and may be appropriately changed and applied as necessary. I can.
이때, 상기 추출 과정은 환류 추출법을 이용한 것일 수 있으나, 이에 제한되지 않고 냉침추출법, 온침추출법, 가압추출법 또는 초음파 분쇄 추출법 또한 사용할 수 있다. 또한, 상기 추출법으로 제조한 추출물 즉, 조추출액에 분획용매를 가한 후에, 예를 들어 헥산, 클로로포름, 에틸아세테이트, 부탄올 및 물 순서로 가한 후에 층분리한헥산분획물, 클로로포름 분획물, 에틸아세테이트 분획물, 부탄올분획물 및 물 분획물을 수득하는 방법을 수행할 수 있다.In this case, the extraction process may be a reflux extraction method, but is not limited thereto, and a cold needle extraction method, a hot needle extraction method, a pressure extraction method, or an ultrasonic grinding extraction method may also be used. In addition, after adding a fractionation solvent to the extract prepared by the above extraction method, that is, to the crude extract, for example, hexane, chloroform, ethyl acetate, butanol and water were added in order, and then layer-separated hexane fraction, chloroform fraction, ethyl acetate fraction, butanol A method of obtaining a fraction and a water fraction can be carried out.
또한, 상기 추출물은 추출 또는 분획과정을 수행한 이후, 감압 여과 과정을 수행하거나 추가로 농축 및/또는 동결건조를 수행하여 농축하거나 용매를 제거할 수 있고, 상기 수득한 조성물은 사용 시까지 급속 냉동 냉장고(deep freezer)에 보관할 수 있다.In addition, after the extraction or fractionation process is performed, the extract can be concentrated or removed by performing a vacuum filtration process or further concentration and/or lyophilization to remove the solvent, and the obtained composition can be rapidly frozen until use. It can be stored in a deep freezer.
본 발명에서 용어 “예방”은 동물의 병리학적 세포의 발생 또는 세포의 손상, 소실의 정도의 감소를 의미한다. 예방은 완전할 수 있으며 또는 부분적일 수도 있다. 본 명세서에서는 본 발명의 조성물을 사용하지 않은 경우와 비교하여 식후 혈당 감소 또는 당뇨병 증세가 완화되는 현상을 의미할 수 있다. In the present invention, the term “prevention” refers to a reduction in the occurrence of pathological cells in an animal, or damage or loss of cells. Prevention can be complete or partial. In the present specification, it may mean a phenomenon in which postprandial blood sugar reduction or diabetes symptoms are alleviated compared to the case where the composition of the present invention is not used.
상기 “치료”는 당뇨병의 증상을 개선하거나, 증상의 진행을 저지하는 것을 의미하며, 통상적으로 사용되는 치료의 의미를 포괄할 수 있다.The “treatment” refers to improving the symptoms of diabetes or preventing the progression of the symptoms, and may encompass the meaning of a commonly used treatment.
본 발명의 다른 측면은 상기 조성물을 포함하는 당뇨병의 예방 또는 치료용 약학적 조성물을 제공한다.Another aspect of the present invention provides a pharmaceutical composition for preventing or treating diabetes comprising the composition.
상기 약학적 조성물은 통상적인 약학적 조성물의 조제에 사용되는 담체, 부형제 및 희석제를 더 포함할 수 있다.The pharmaceutical composition may further include a carrier, an excipient, and a diluent used in the preparation of a conventional pharmaceutical composition.
상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 또는 광물유를 들 수 있으나, 이에 한정되는 것은 아니다.Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil, but are not limited thereto.
또한, 상기 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제제화 하여 사용할 수 있다. In addition, the composition may be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterile injectable solutions.
상기 경구 투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물과 이의 분획물들에 적어도 하나 이상의 부형제, 예컨대, 전분, 칼슘카보네이트, 수크로오스, 락토오스, 또는 젤라틴 등을 혼합하여 조제할 수 있다. 상기 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제가 사용될 수도 있다.The solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose, lactose, in the composition and its fractions, Alternatively, it can be prepared by mixing gelatin or the like. In addition to the above excipients, lubricants such as magnesium stearate and talc may be used.
상기 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 사용될 수 있으며, 단순희석제인 물, 리퀴드 파라핀 외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. As the liquid formulation for oral administration, a suspension, a liquid solution, an emulsion, a syrup, etc. may be used, and various excipients, such as a wetting agent, a sweetening agent, a fragrance, a preservative, etc., may be used in addition to water and liquid paraffin, which are simple diluents. have.
상기 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 사용될 수 있다. 상기 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르가 사용될 수 있다. 상기 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴이 사용될 수 있다.The formulation for parenteral administration may be a sterile aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized formulation, or a suppository. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, and glycerogelatin may be used.
상기 혈당 강하용 조성물을 포함하는 약학적 조성물은 약제학적으로 유효한 양이 대상체에 투여될 수 있다. 상기 “약제학적으로 유효한 양”은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다.The pharmaceutical composition including the composition for lowering blood sugar may be administered to a subject in a pharmaceutically effective amount. The “pharmaceutically effective amount” refers to an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, drug activity, drug Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, factors including co-used drugs and other factors well known in the medical field.
상기 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 바람직하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is preferable to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
본 발명의 치료용 조성물의 바람직한 투여량은 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 본원발명이 속하는 기술분야에서 통상의 지식을 가진 자에 의해 적절하게 선택될 수 있다. 바람직하게는 본 발명의 치료용 조성물이 1일 5 내지 15g 투여되는 것이 바람직하다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있으나, 공복에 하루 세번 1회 3g씩 투여하는 경우가 가장 효과가 우수하다. 상기 투여량과 투여횟수는 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The preferred dosage of the therapeutic composition of the present invention varies depending on the condition and weight, the degree of disease, the form of the drug, the route of administration and the duration, but may be appropriately selected by a person having ordinary knowledge in the technical field to which the present invention belongs. have. Preferably, the therapeutic composition of the present invention is preferably administered 5 to 15g per day. Administration may be administered once a day, or may be divided several times, but the best effect is when 3g is administered three times a day on an empty stomach. The dosage and the number of administrations do not limit the scope of the present invention in any way.
본 발명의 또 다른 측면은, 상기 조성물을 포함하는, 당뇨병의 예방 또는 개선용 식품 조성물을 제공한다.Another aspect of the present invention provides a food composition for preventing or improving diabetes, comprising the composition.
본 발명에서 식품이라 함은 영양소를 한 가지 또는 그 이상 함유하고 있는 천연물 또는 가공품을 의미하며, 바람직하게는 어느 정도의 가공 공정을 거쳐 직접 먹을 수 있는 상태가 된 것을 의미하며, 통상적인 의미로서, 건강기능식품, 음료, 식품 첨가제 및 음료 첨가제를 모두 포함하는 의도이다.In the present invention, the term food refers to a natural product or processed product containing one or more nutrients, and preferably refers to a state that can be eaten directly through a certain degree of processing, and as a general meaning, It is intended to include all functional foods, beverages, food additives and beverage additives.
본 발명의 식품은 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강기능식품 등이 있다. 추가로, 본 발명에서 식품에는 특수영양식품(예, 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예, 라면류, 국수류 등), 건강보조식품, 조미식품(예, 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예,스넥류), 유가공품(예, 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예,과실,채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등)을 포함하나 이에 한정되지 않는다.상기 식품, 건강기능식품, 음료, 식품 첨가제 및 음료 첨가제는 통상의 제조방법으로 제조될 수 있다.Foods of the present invention include, for example, various foods, beverages, gums, teas, vitamin complexes, and health functional foods. In addition, foods in the present invention include special nutritional foods (e.g., formulas, infant foods, etc.), processed meat products, fish meat products, tofu, muk, noodles (e.g., ramen, noodles, etc.), health supplements, seasoning foods ( Example, soy sauce, miso, red pepper paste, mixed sauce, etc.), sauces, confectionery (eg, snacks), dairy products (eg, fermented milk, cheese, etc.), other processed foods, kimchi, pickles (various kimchi, pickles, etc.), beverages ( Examples include, but are not limited to, fruit, vegetable beverages, soy milk, fermented beverages, etc.), and natural seasonings (e.g., ramen soup, etc.). The foods, health functional foods, beverages, food additives and beverage additives are conventionally manufactured. It can be manufactured by the method.
본 발명에서 건강기능식품이란 식품에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 식품의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 식품군이나 식품 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 식품을 의미한다. 상기 건강기능식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강기능식품의 제조에 통상적으로 사용되는 적절한 담체, 부형제 및 희석제를 더욱 포함할 수 있다.In the present invention, the health functional food refers to a food group or food composition that has added value to act and express the function of the food by using physical, biochemical, biotechnological techniques, etc. It refers to foods that are designed and processed to sufficiently express the gymnastic function for recovery, etc. to the living body. The health functional food may contain food additives acceptable for food, and may further include suitable carriers, excipients and diluents commonly used in the manufacture of health functional foods.
본 발명에서 음료란 갈증을 해소하거나 맛을 즐기기 위하여 마시는 것의 총칭을 의미하며 건강기능음료를 포함하는 의도이다. 상기 음료는 지시된 비율로 필수 성분으로서 상기 조성물을 유효성분으로 포함하는 것 외에 다른 성분에는 특별한 제한이 없으며, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.In the present invention, a beverage refers to a generic term for drinking to quench thirst or to enjoy taste, and is intended to include a health functional beverage. The beverage is an essential component in the indicated ratio, in addition to containing the composition as an active ingredient, there is no particular limitation on other components, and may contain various flavoring agents or natural carbohydrates as an additional component, like a conventional beverage.
상기의 천연 탄수화물의 예는 모노사카라이드, 예를 들어 포도당, 과당 등 디사카라이드, 예를 들어 말토스, 수크로스 등 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 1 내지 20g, 바람직하게는 5 내지 12g일 수 있다. 그밖에 본 발명의 조성물은 천연 과일 주스, 과일 쥬스 음료, 야채 음료의 제조를 위한 과육을 추가로 함유할 수 있다.Examples of the above natural carbohydrates include monosaccharides, such as disaccharides such as glucose and fructose, such as maltose, sucrose, and the like, and polysaccharides, such as dextrin, cyclodextrin, and the like, and conventional sugars, and These are sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The ratio of the natural carbohydrate may be generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention In addition, the composition of the present invention is used to prepare natural fruit juice, fruit juice beverage, and vegetable beverage. It may contain additional pulp.
상기 외에 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 이러한 성분을 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하지 않지만, 본 발명의 조성물 100 중량부 당 0 내지 20 중량부 범위에서 선택될 수 있다.In addition to the above, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and heavy weight agents (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid, and Salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like may be contained. These components may be used independently or in combination. The proportion of these additives is not so important, but may be selected in the range of 0 to 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명에서 건강기능음료란 음료에 물리적, 생화학적, 생물공학적 수법 등을 이용하여 해당 음료의 기능을 특정 목적에 작용, 발현하도록 부가가치를 부여한 음료 군이나 음료 조성이 갖는 생체방어리듬조절, 질병방지와 회복 등에 관한 신체조절기능을 생체에 대하여 충분히 발현하도록 설계하여 가공한 음료를 의미한다.In the present invention, the health functional beverage refers to a beverage group or a beverage group that has added value to act and express the function of the beverage for a specific purpose by using physical, biochemical, and biotechnological techniques, etc. It refers to a beverage that has been designed and processed to sufficiently express body control functions related to and recovery.
본 발명의 조성물은 인체에 무해한 천연 원료만을 포함하여 제조되는 것으로서, 상기 천연 원료의 유효성분들은 혈당 상승과 관련이 있는 α-아밀라아제(α-amylase) 및 α-글루코시다아제(α-glucosidase)의 저해활성을 가지고, 꾸준히 복용하는 경우 상기 유효성분들의 상호작용에 의하여 사용자의 식후 혈당 상승을 억제하는 효과가 것을 특징으로 한다.The composition of the present invention is prepared containing only natural raw materials that are harmless to the human body, and the active ingredients of the natural raw materials include α-amylase and α-glucosidase, which are associated with an increase in blood sugar. It has an inhibitory activity and, when taken steadily, has an effect of suppressing an increase in blood sugar after a meal by the user by the interaction of the active ingredients.
또한, 상기 조성물은 천연물로부터 유래한 것으로서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 장기간 사용이 가능하다.In addition, the composition is derived from a natural product and is not toxic, and even when applied to the human body, it does not cause side effects, so it can be used for a long time.
본 발명의 효과는 상기한 효과로 한정되는 것은 아니며, 본 발명의 상세한 설명 또는 청구범위에 기재된 발명의 구성으로부터 추론 가능한 모든 효과를 포함하는 것으로 이해되어야 한다.The effects of the present invention are not limited to the above effects, and should be understood to include all effects that can be deduced from the configuration of the invention described in the detailed description or claims of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited by the following examples.
실시예 1. 본 발명의 혈당 강하용 조성물의 제조Example 1. Preparation of the composition for lowering blood sugar of the present invention
본 발명의 혈당 강하용 조성물을 제조하기 위하여, 먼저 황기, 도라지, 칡, 진피, 구기자, 둥굴레, 맥문동 및 마의 천연물 유래 추출물을 제조하였다.In order to prepare the composition for lowering blood sugar of the present invention, extracts derived from natural products of Astragalus, bellflower, arrowroot, dermis, goji berries, donggulle, liquorice and hemp were prepared.
구체적으로, 황기 50 중량부, 도라지 50 중량부, 칡 50 중량부, 진피 50 중량부, 구기자 100 중량부, 둥굴레 50 중량부, 맥문동 50 중량부 및 마 100 중량부 각각에 대하여 동일 중량부의 정제수를 첨가하고 열수 추출하여 추출물을 제조하였다.Specifically, 50 parts by weight of Astragalus kelp, 50 parts by weight of bellflower, 50 parts by weight of arrowroot, 50 parts by weight of dermis, 100 parts by weight of wolfberry, 50 parts by weight of Donggulae, 50 parts by weight of licorice, and 100 parts by weight of hemp were treated with equal parts by weight of purified water. It was added and extracted with hot water to prepare an extract.
이때, 상기 재료의 특성에 따라 각기 조건을 다음과 같이 다르게 하여 순행식 무압력 추출기를 이용해 추출을 진행하였다. At this time, the extraction was performed using a forward pressureless extractor by varying the conditions as follows according to the characteristics of the material.
구체적으로, 황기 및 도라지는 각 50 중량부에 정제수 50 중량부씩 첨가한 후 100℃에서 6시간동안 추출하였고, 칡 및 진피는 각 50 중량부에 정제수 50 중량부를 첨가한 후 98℃에서 4시간동안 추출하였으며, 구기자 100 중량부 및 50 중량부에 같은 중량부의 정제수를 첨가한 후 95℃에서 6시간동안 추출하였고, 맥문동 50 중량부 및 마 100 중량부에 같은 중량부의 정제수를 첨가한 후 92℃에서 6시간동안 추출하여 제조하였다.Specifically, Astragalus and bellflower were added to 50 parts by weight of each 50 parts by weight of purified water and extracted for 6 hours at 100°C, and arrowroot and dermis were added to 50 parts by weight of each 50 parts by weight of purified water and then at 98°C for 4 hours. Extracted, 100 parts by weight and 50 parts by weight of Gugija were added, and then extracted for 6 hours at 95°C, and 50 parts by weight and 100 parts by weight of hemp were added to the same part by weight of purified water at 92°C. It was prepared by extraction for 6 hours.
비교예 1 및 2. 마 또는 둥굴레를 제외한 조성물의 제조Comparative Examples 1 and 2. Preparation of a composition excluding hemp or round bridle
상기 실시예 1의 제조방법 중, 당뇨병에 효과가 있는 것으로 알려진 마 또는 둥굴레를 포함하지 않고 제조한 것을 제외하고는 동일한 방법으로 본 발명 비교예 1(마 제외) 및 2(둥굴레 제외)의 조성물을 제조하였다.In the preparation method of Example 1, the compositions of Comparative Examples 1 (excluding hemp) and 2 (excluding hemp) were prepared in the same manner, except that hemp or donggulle, which is known to be effective for diabetes, was not prepared. Was prepared.
비교예 3. 진피, 도라지 및 맥문동을 제외한 조성물의 제조Comparative Example 3. Preparation of a composition excluding dermis, bellflower, and licorice
상기 실시예 1의 제조방법 중, 기침, 결핵 등 기관지에 효과가 있는 것으로만 알려져 있을 뿐, 당뇨병이나 혈당 관련 효과에 대해서는 개시된 바 없는 진피, 도라지 및 맥문동을 제외하였을 때의 효과 차이를 확인하고자 하였다. 이를 위해 진피, 도라지 및 맥문동을 포함하지 않고 제조한 것을 제외하고는 동일한 방법으로 본 발명 비교예 3의 조성물을 제조하였다.Among the manufacturing methods of Example 1, only known to have an effect on bronchi such as cough and tuberculosis, and for diabetes or blood sugar-related effects, it was intended to confirm the difference in effects when excluding the dermis, bellflower, and pulmonary sinus, which have not been disclosed. . To this end, the composition of Comparative Example 3 of the present invention was prepared by the same method except that it was prepared without including the dermis, bellflower, and licorice.
비교예 4. 추출조건을 통일한 조성물의 제조Comparative Example 4. Preparation of a composition in which extraction conditions were unified
상기 실시예 1의 제조방법은 각 재료별로 추출 조건을 달리하였는 바, 이러한 추출조건을 통일하여 각 재료의 특성을 고려하지 않고 제조한 경우 효과에 차이가 발생하는지를 확인하기 위하여, 모든 재료를 100℃에서 6시간동안 추출하였고, 이를 제외하고는 동일한 방법으로 본 발명 비교예 4의 조성물을 제조하였다.In the manufacturing method of Example 1, the extraction conditions were different for each material, and in order to confirm whether a difference in effect occurs when the extraction conditions are unified and manufactured without considering the characteristics of each material, all materials were 100°C. Extracted for 6 hours, except for this, to prepare the composition of the present invention Comparative Example 4 in the same method.
실험예 1. 본 발명 조성물의 혈당 상승 억제효과 확인Experimental Example 1. Confirmation of the inhibitory effect of the composition of the present invention on increasing blood sugar
본 발명의 조성물을 꾸준히 섭취하는 경우, 식후 혈당 상승 억제 효과가 있는지를 확인하였다.When the composition of the present invention is continuously ingested, it was confirmed whether there is an effect of suppressing an increase in blood sugar after eating.
구체적으로, 평소 식후 2시간 내에 혈당이 280mg/dl 정도인 당뇨인 10명을 선정하고, 상기 당뇨인을 대상으로 각 2명씩 5그룹으로 나누어 상기 실시예 1 및 비교예 1 내지 4의 조성물을 30일 동안 매일 꾸준히 섭취하게 하였다.Specifically, 10 diabetic people with a blood sugar of about 280 mg/dl were selected within 2 hours after a meal, and the composition of Example 1 and Comparative Examples 1 to 4 was divided into 5 groups for each of 2 people for 30 days. The daily intake was continued.
30일이 경과한 이후, 백미 200g으로 밥을 조리하고, 별도의 반찬 없이 물과 밥 만을 섭취하도록 하였다. 이후 섭취가 완료된 순간부터 시간 경과에 따른 혈당을 평가하고, 그 결과를 하기 표 1에 나타내었다. 혈당 평가는 혈당측정기(아큐첵)를 이용하여 측정한 값의 평균이고, 단위는 mg/dl이며, 소수점 아래는 반올림하였다. After 30 days had elapsed, rice was cooked with 200 g of white rice, and only water and rice were consumed without separate side dishes. After the intake is completed, the blood glucose over time was evaluated, and the results are shown in Table 1 below. Blood glucose evaluation is the average of the values measured using a blood glucose meter (Accuchek), the unit is mg/dl, and the decimal point is rounded.
그 결과, 상기 표 1에 나타난 바와 같이 본 발명의 실시예 1의 조성물을 섭취한 실험군은 혈당의 최대치가 섭취 전(280mg/dl)과 비교할 때 현저히 낮아졌으며, 당뇨에 효과가 있는 것으로 알려진 마 또는 둥굴레를 제외한 비교예 1 및 2의 경우는 모두 섭취전과 비교할 때 다소간의 효과가 있었으나, 식후 최대 혈당치 및 정상 혈당으로의 회복 속도 모두 실시예 1에 비해 떨어지는 효과를 보였다.한편, 기관지 효과 등만 알려지고, 당뇨병이나 혈당 관련 효과에 대해서는 알려진 바 없는 진피, 도라지 및 맥문동을 제외한 비교예 3의 경우 최초 혈당 증가속도는 비교예 1 및 2보다 빨랐으나, 오히려 혈당 최대치는 비교예 1 및 2보다 낮았다.As a result, as shown in Table 1 above, in the experimental group ingesting the composition of Example 1 of the present invention, the maximum value of blood sugar was significantly lowered compared to before ingestion (280mg/dl), and hemp or In the case of Comparative Examples 1 and 2 except for Dunggulle, there was some effect compared to before ingestion, but both the maximum blood sugar level after eating and the recovery rate to normal blood sugar showed a lower effect compared to Example 1. Meanwhile, only the bronchial effect, etc. were known. In the case of Comparative Example 3, excluding the dermis, bellflower, and rhizome, whose diabetes or blood sugar-related effects were unknown, the initial blood sugar increase rate was faster than that of Comparative Examples 1 and 2, but the maximum blood sugar value was lower than that of Comparative Examples 1 and 2.
마지막으로, 추출 조건을 달리한 비교예 4의 경우 모든 시점에 있어서 본 발명 실시예 1의 조성물보다 효과가 뒤쳐지는 것을 확인하였는 바, 이는 각 천연물을 추출하는 조건에 따라, 각 천연물에 함유된 유효성분이 추출되는 양 및 조성에 현저한 차이를 보이기 때문인 것으로 보인다.Finally, in the case of Comparative Example 4 with different extraction conditions, it was confirmed that the effect was inferior to that of the composition of Example 1 of the present invention at all time points, which is, depending on the conditions for extracting each natural product, the effectiveness contained in each natural product. This seems to be because there is a remarkable difference in the amount and composition of the powder extracted.
실험예 2. 당뇨병 개선효과 확인Experimental Example 2. Diabetes improvement effect confirmation
본 발명 조성물의 당뇨병 개선효과를 확인하기 위하여, α-아밀라아제(α-amylase) 및 α-글루코시다아제(α-glucosidase)의 저해활성을 측정하여 전분 분해억제 활성을 평가하였다. In order to confirm the diabetes improvement effect of the composition of the present invention, the inhibitory activity of α-amylase and α-glucosidase was measured to evaluate the starch decomposition inhibitory activity.
상기 α-아밀라아제는 Bacillus amyloiquifaciens에서 유래한 것이고, α-글루코시다아제는 Aspergillus niger 유래의 효소로서, 국내의 전분 가공업체(ApisBio Co. Deagu, Korea)로부터 구입하여 사용하였다.The α-amylase is derived from Bacillus amyloiquifaciens , and α-glucosidase is an enzyme derived from Aspergillus niger , and was purchased and used from a domestic starch processing company (ApisBio Co. Deagu, Korea).
α-아밀라아제(α-Amylase) 저해 활성은 시료 2.5μl와 50mM phosphate buffer(pH 6.8)로 희석한 α-아밀라아제(0.25U/ml) 25μl를 혼합하여 37℃에서 10분간 전처리한 후, 0.5% 수용성 녹말(Samchun Chemicals Co., Korea) 25μl를 가하여 37℃에서 10분간 반응하였다. 이후, 2N 아세트산 25μl를 가하여 반응을 정지시켰으며, 반응액에 0.75% KI/I2 용액 10μl를 가하여 발색하였다. 발색액은 540nm에서 흡광도를 측정하여 저해활성을 확인하였다.α-amylase inhibitory activity was obtained by mixing 2.5 μl of a sample and 25 μl of α-amylase (0.25 U/ml) diluted with 50 mM phosphate buffer (pH 6.8), pretreatment at 37° C. for 10 minutes, and 0.5% water solubility. 25 μl of starch (Samchun Chemicals Co., Korea) was added and reacted at 37°C for 10 minutes. Thereafter, 25 μl of 2N acetic acid was added to stop the reaction, and 10 μl of a 0.75% KI/I2 solution was added to the reaction solution to develop color. The color developing solution was confirmed to have inhibitory activity by measuring absorbance at 540 nm.
α-글루코시다아제 저해활성은 시료 2.5μl와 50mM 초산 나트륨 완충액(sodium acetate buffer)(pH 5.6)로 희석한 α-글루코시다아제(0.25U/ml) 25μl를 혼합하여 37℃에서 10분간 전처리하고, 1mM pNPG 용액 25μl를 가하여 60℃에서 10분간 반응하였다. 이후, 1M NaOH 25μl를 가하여 반응을 정지시키고, 405nm에서 흡광도를 측정하여 β아밀라아제 저해활성과 동일한 방법으로 저해활성을 확인하였다.α-glucosidase inhibitory activity was pretreated at 37°C for 10 minutes by mixing 2.5 μl of a sample and 25 μl of α-glucosidase (0.25 U/ml) diluted with 50 mM sodium acetate buffer (pH 5.6). , 25 μl of a 1 mM pNPG solution was added and reacted at 60° C. for 10 minutes. Thereafter, 25 μl of 1M NaOH was added to stop the reaction, and the absorbance was measured at 405 nm to confirm the inhibitory activity in the same manner as the β-amylase inhibitory activity.
상기한 방법을 통해 실시예 1 및 비교예 4 조성물과 이눌린이 풍부하여 혈당 강하 효과가 있는 것으로 알려진 돼지감자의 추출물을 대상으로 각각 전분 분해억제 활성을 측정하였으며, 그 결과를 표 2에 나타내었다.Through the above-described method, the composition of Example 1 and Comparative Example 4 and the extracts of pork potatoes known to have a blood sugar-lowering effect because they are rich in inulin were measured for their starch decomposition inhibitory activity, respectively, and the results are shown in Table 2.
저해율(%)α-amylase
Inhibition rate (%)
저해율(%)α-glucosidase
Inhibition rate (%)
상기 표 2에 나타난 바와 같이, 들어가는 추출물의 재료는 동일하나, 추출 조건만을 달리한 비교예 4가 실시예 1에 비해 현저히 낮은 효과를 보이는 것을 확인하였으며, 실시예 1 및 비교예 4 모두 혈당강하 효과가 있는 돼지감자 추출물보다 현저히 우수한 전분 분해억제 활성을 갖는 것을 확인하였다.전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다. 예를 들어, 단일형으로 설명되어 있는 각 구성 요소는 분산되어 실시될 수도 있으며, 마찬가지로 분산된 것으로 설명되어 있는 구성 요소들도 결합된 형태로 실시될 수 있다.As shown in Table 2, it was confirmed that the material of the extract to be entered was the same, but Comparative Example 4, in which only the extraction conditions were different, showed a significantly lower effect compared to Example 1, and both Example 1 and Comparative Example 4 had the effect of lowering blood sugar. It was confirmed that it has a remarkably superior starch decomposition inhibitory activity than the pork potato extract. The description of the present invention described above is for illustration purposes, and those of ordinary skill in the art to which the present invention pertains to the technical idea or essential It will be appreciated that it is possible to easily transform into other specific forms without changing the features. Therefore, it should be understood that the embodiments described above are illustrative in all respects and not limiting. For example, each component described as a single type may be implemented in a distributed manner, and similarly, components described as being distributed may also be implemented in a combined form.
본 발명의 범위는 후술하는 청구범위에 의하여 나타내어지며, 청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and the concept of equivalents thereof should be construed as being included in the scope of the present invention.
Claims (5)
상기 황기 및 도라지는 각 50 중량부에 정제수 50 중량부씩 첨가한 후 100℃에서 6시간동안 열수 추출하였고,
상기 칡 및 진피는 각 50 중량부에 정제수 50 중량부를 첨가한 후 98℃에서 4시간동안 열수 추출하였으며,
상기 구기자 100 중량부 및 50 중량부에 같은 중량부의 정제수를 첨가한 후 95℃에서 6시간동안 열수 추출하였고,
상기 맥문동 50 중량부 및 마 100 중량부에 같은 중량부의 정제수를 첨가한 후 92℃에서 6시간동안 추출하여 제조한 것인, 혈당 강하용 조성물.50 parts by weight of Astragalus, 50 parts by weight of bellflower, 50 parts by weight of arrowroot, 50 parts by weight of dermis, 100 parts by weight of wolfberry, 50 parts by weight of Donggulle, 50 parts by weight of lichen, and 100 parts by weight of hemp extract,
After adding 50 parts by weight of purified water to 50 parts by weight of each 50 parts by weight of Astragalus and bellflower, hot water was extracted at 100° C. for 6 hours,
The arrowroot and dermis were extracted with hot water at 98° C. for 4 hours after adding 50 parts by weight of purified water to 50 parts by weight of each,
After adding purified water in an equal weight part to 100 parts by weight and 50 parts by weight of the wolfberry, hot water extraction was performed at 95° C. for 6 hours,
A composition for lowering blood sugar prepared by adding purified water in the same weight part to 50 parts by weight of lichen and 100 parts by weight of hemp and then extracting at 92° C. for 6 hours.
칡 및 진피 각 50 중량부에 정제수 50 중량부를 첨가한 후 98℃에서 4시간동안 열수 추출하는 단계;
구기자 100 중량부 및 50 중량부에 같은 중량부의 정제수를 첨가한 후 95℃에서 6시간동안 열수 추출하는 단계; 및
맥문동 50 중량부 및 마 100 중량부에 같은 중량부의 정제수를 첨가한 후 92℃에서 6시간동안 추출하는 단계;를 포함하는, 혈당 강하용 조성물의 제조방법.Adding 50 parts by weight of purified water to 50 parts by weight of astragalus and bellflower and extracting hot water at 100° C. for 6 hours;
Adding 50 parts by weight of purified water to 50 parts by weight of arrowroot and dermis and extracting hot water at 98° C. for 4 hours;
Adding purified water to 100 parts by weight and 50 parts by weight of wolfberry and extracting hot water at 95° C. for 6 hours; And
Extracting for 6 hours at 92° C. after adding purified water in the same weight part to 50 parts by weight of lichen and 100 parts by weight of hemp; comprising, a method for preparing a composition for lowering blood sugar.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200112986A KR102203094B1 (en) | 2020-09-04 | 2020-09-04 | Composition for preventing and improving menstrual pain and skin troubles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200112986A KR102203094B1 (en) | 2020-09-04 | 2020-09-04 | Composition for preventing and improving menstrual pain and skin troubles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102203094B1 true KR102203094B1 (en) | 2021-01-14 |
Family
ID=74141584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200112986A KR102203094B1 (en) | 2020-09-04 | 2020-09-04 | Composition for preventing and improving menstrual pain and skin troubles |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102203094B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0126431B1 (en) * | 1994-07-21 | 1997-12-24 | 한동근 | Healthy food having effect of falling of blood sugar |
| KR100542809B1 (en) * | 2002-07-04 | 2006-01-11 | 주식회사 싸이클로젠 | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus |
| KR100869443B1 (en) | 2007-04-09 | 2008-11-18 | 고려대학교 산학협력단 | Hypoglycemic composition containing the extracts of mulberry leaves, Cinnamomum cassia barks and grape seeds |
| KR20130126022A (en) * | 2012-05-10 | 2013-11-20 | 주식회사 파낙스코리아 | The anti-diabetic composition mainly containing extracts of kudzu root, solomon's seal and e. senticosus |
| KR20170061430A (en) * | 2015-11-26 | 2017-06-05 | 주식회사 장생도라지 | Old Platycodon Composit Composition Enhanced Antidiabetic Activity |
-
2020
- 2020-09-04 KR KR1020200112986A patent/KR102203094B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0126431B1 (en) * | 1994-07-21 | 1997-12-24 | 한동근 | Healthy food having effect of falling of blood sugar |
| KR100542809B1 (en) * | 2002-07-04 | 2006-01-11 | 주식회사 싸이클로젠 | Composition of crude drug, method of preparing the same and pharmaceutical preparation including the same for curing diabetes mellitus |
| KR100869443B1 (en) | 2007-04-09 | 2008-11-18 | 고려대학교 산학협력단 | Hypoglycemic composition containing the extracts of mulberry leaves, Cinnamomum cassia barks and grape seeds |
| KR20130126022A (en) * | 2012-05-10 | 2013-11-20 | 주식회사 파낙스코리아 | The anti-diabetic composition mainly containing extracts of kudzu root, solomon's seal and e. senticosus |
| KR20170061430A (en) * | 2015-11-26 | 2017-06-05 | 주식회사 장생도라지 | Old Platycodon Composit Composition Enhanced Antidiabetic Activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102511869B (en) | Thickened red jujube ginger pulp | |
| KR101433188B1 (en) | Composition For Relieving Alcohol-induced Hangover Comprising Starch, Amino Acids, Active Complex Vitamin And Oriental Herb Medicine materials AND, The Manufacturing Method Thereof | |
| KR101144059B1 (en) | Composition for prevention or treatment of diabete or obesity comprising Punica granatum extract and red ginseng extract | |
| CN105112265A (en) | Health-care fig wine and preparation method thereof | |
| CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
| CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
| KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
| CN110051815A (en) | A kind of auxiliary hyperglycemic food ball and preparation method thereof | |
| CN104247913A (en) | Health rice vermicelli | |
| KR100947278B1 (en) | A carbohydrate and lipid absorption inhibitory nelumbo composition and its manufacturing process thereof | |
| KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
| CN109170863A (en) | A kind of functional sugar ferment and preparation method thereof | |
| CN103355444B (en) | A kind of invigorating the spleen qi-tonifying health-care tea cream and preparation method | |
| CN105029553A (en) | Fruit juice-egg-calcium traditional Chinese medicine health beverage and preparation method thereof | |
| CN102511876B (en) | Hawthorn red jujube thick syrup and production process thereof | |
| CN105176773A (en) | Pumpkin wine capable of adjusting blood glucose and making method thereof | |
| KR102203094B1 (en) | Composition for preventing and improving menstrual pain and skin troubles | |
| KR101391647B1 (en) | Anti obesity composition | |
| CN107712890A (en) | A kind of antitoxic heart-soothing and sedative cream taste and preparation method thereof | |
| KR100337472B1 (en) | Health food beverage composition containing prickly pear extract | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| KR102080204B1 (en) | Clathrate compound of Schisandra chinensis extract and method for its production | |
| CN104673573A (en) | Wine with diabetes prevention and treatment function and preparation method thereof | |
| CN110876717A (en) | Preparation method of product capable of stabilizing blood sugar | |
| CN109662314A (en) | A kind of auxiliary hyperglycemic, compound Hubei Chinese flowering crabapple leaf functional food of reducing blood lipid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |